Manufacturer
DUOPHARMA (M) SDN. BHD.
Contents
Morphine sulfate
Indication
Moderate to severe pain, Postoperative pain, Moderate to severe pain, Pain associated with myocardial infarction, Postoperative pain, Severe cancer pain, Acute pulmonary oedema, Premedication in surgery, Severe cancer pain.
Instruction
Administer via SC/IM/IV infusion.
Drug interaction
Increased depressant effects with other CNS depressants (e.g. sedatives, hypnotics, general anaesthesia, phenothiazines, tranquilisers). May enhance the neuromuscular blocking action of skeletal muscle relaxants. Reduced analgesic effect with mixed agonist/antagonist opioid analgesics (e.g. buprenorphine, nalbuphine, pentazocine). Increased plasma concentrations with cimetidine. Reduced plasma concentration with rifampicin, ritonavir. Decreased therapeutic effect of diuretics. Increased plasma concentration with cisapride. Increased risk of orthostatic hypotension with antihypertensive agents. Increased risk of severe constipation and CNS depression with antidiarrhoeal agents.Potentially Fatal: Enhanced depressant effect with MAOIs.
Malaysia
